

TABLE OF CONTENTS

Description	Page
Acknowledgements	I-III
List of Tables	IV-V
List of Figures	VI-IX
List of Abbreviations	X-XI
CHAPTER I: INTRODUCTION	1-10
1.1. Introduction	1
1.2. Motivation for Taking up the Present Research Work	4
1.3. Objectives of the Present Research Work	5
1.4. References	6
CHAPTER II: BACKGROUND AND LITERATURE REVIEW	11-43
2.1. Nuances of Nano-Enabled Drug Delivery Systems	11
2.2. Drug Delivery Systems Selected for the Study	12
2.3. Hypertension	29
2.4. Detailed Profile of Drug and Excipients Used in the Present Study	32
2.5. References	35
CHAPTER III: ANALYTICAL AND BIOANALYTICAL METHOD DEVELOPMENT	44-69
Abstract	44
3.1. Introduction	45
3.2. Experimental Methods	46
3.3. Analytical Method Development of Lercanidipine	46
3.4. Analytical Method Validation	49
3.5. Bioanalytical Method Development of Lercanidipine	51
3.6. Bioanalytical Method Validation	54
3.7. Results and Discussion	57
3.8. Conclusions	67
3.9. References	68
CHAPTER IV: FORMULATION OF LERCANIDIPINE LOADED NANOPROLIPOSOMES	70-136
Abstract	70
4.1. Introduction	71

4.2. Experimental Methodology	74
4.3. Formulation Development	76
4.4. Formulation Optimization	78
4.5. Formulation Characterization	80
4.6. Results and Discussion	90
4.7. Conclusions	129
4.8. References	130
CHAPTER V: FORMULATION OF LERCANIDIPINE LOADED NANOPARTICLES	137-197
Abstract	137
5.1. Introduction	138
5.2. Experimental Methodology	140
5.3. Formulation Development	141
5.4. Formulation Optimization	143
5.5. Formulation Characterization	144
5.6. Results and Discussion	151
5.7. Conclusions	191
5.8. References	192
CHAPTER VI: SUMMARY AND CONCLUSIONS	198-208
6.1. Summary and Conclusions	198
6.2. Future Directions	207
Publications and Presentations	209-211